Skip to main content

Cortexyme, Inc. (CRTX)

NASDAQ: CRTX · IEX Real-Time Price · USD
87.79 -2.63 (-2.91%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap2.61B
Revenue (ttm)n/a
Net Income (ttm)-86.90M
Shares Out29.69M
EPS (ttm)-2.94
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume536,426
Open91.08
Previous Close90.42
Day's Range87.60 - 93.93
52-Week Range26.66 - 121.98
Beta0.84
AnalystsBuy
Price Target97.71 (+11.3%)
Est. Earnings DateNov 9, 2021

About CRTX

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

IndustryBiotechnology
IPO DateMay 9, 2019
Employees37
Stock ExchangeNASDAQ
Ticker SymbolCRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for Cortexyme stock is "Buy." The 12-month stock price forecast is 97.71, which is an increase of 11.30% from the latest price.

Price Target
$97.71
(11.30% upside)
Analyst Consensus: Buy

News

Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a ...

1 week ago - Business Wire

Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a ...

1 week ago - Business Wire

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzhei...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a ...

3 weeks ago - Business Wire

Cortexyme to Present at Annual Biomarkers for Alzheimer's Disease Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a ...

1 month ago - Business Wire

Cortexyme: Shifting The Odds In Your Favor So Your Best Case Outcome Is Three Times Higher Than Your Worst Case

Screen capture via Cortexyme animation.  A Bigger Bubble Than The Late '90s

1 month ago - Benzinga

Cortexyme Provides Business Update and Reports Second Quarter 2021 Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a ...

1 month ago - Business Wire

Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 202...

1 month ago - Business Wire

Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen a...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 20...

1 month ago - Business Wire

Cortexyme Selects 3CLpro Inhibitor As COVID-19 Candidate

Cortexyme Inc (NASDAQ: CRTX) has selected COR803 to further evaluate for coronavirus infections, including COVID-19 disease. COR803 is a novel patent-pending small molecule 3CLpro inhibitor, and 3CLpro ...

1 month ago - Benzinga

Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 20...

1 month ago - Business Wire

Cortexyme to Present New Data at AAIC 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 20...

1 month ago - Business Wire

Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 20...

1 month ago - Business Wire

Cortexyme to Host Symposium at AAIC 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 20...

2 months ago - Business Wire

Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 202...

2 months ago - Business Wire

Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 202...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 202...

3 months ago - Business Wire

Cortexyme to Present at Investor Conferences in June 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 202...

3 months ago - Business Wire

Cortexyme Provides Business Update and Reports First Quarter 2021 Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it belie...

4 months ago - Business Wire

Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021

4 months ago - Business Wire

Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a gr...

5 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are ...

5 months ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX).  Such investors are advised to co...

6 months ago - PRNewsWire

Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, today announced Chris Low...

6 months ago - Business Wire

Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer's Disease Data Presentation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, announced that it has par...

6 months ago - Business Wire

7 Small Stocks Up Big Can Still Double From Here, Analysts Say

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

6 months ago - Investors Business Daily

Cortexyme Stops Enrollment In Mid-Stage Atuzaginstat Study In Alzheimer's Disease

Following the review of hepatic adverse events, the FDA has instituted a partial clinical hold impacting the open-label extension (OLE) phase of Phase 2/3 GAIN trial of Cortexyme Inc (NASDAQ: CRTX) eval...

7 months ago - Benzinga